Biopharmaceutical company Insmed Incorporated (Nasdaq:INSM) reported on Tuesday the receipt of the patent from the US Patent and Trademark Office (USPTO) for certain uses of ARIKAYCE (amikacin liposome inhalation suspension) for treating MAC lung disease in adult patients under combination antibacterial drug regimen.

The claims of the patent, which has been assigned the number No. 10,251,900, relate in part to methods for treating Mycobacterium avium complex (MAC) lung disease via administration of ARIKAYCE to patients previously unresponsive to MAC therapy.

This is the USPTO's tenth patent for ARIKAYCE in MAC lung disease and the second with an expiry date of 15 May 2035. The company's global patent portfolio also includes eight issued/allowed patents for ARIKAYCE in Japan and five in Europe, with patent protection secured to 2033 and 2035, respectively.

According to the company, the methods described in the new US patent relate in part to the treatment of MAC lung infections in patients previously unresponsive to MAC therapy, where the treatment includes achieving a negative MAC sputum culture in the patient. The methods entail administering ARIKAYCE to the patient in combination with a macrolide antibiotic and ethambutol. ARIKAYCE is a novel, inhaled, once-daily formulation of amikacin, an established antibiotic.

Mycobacterium avium complex (MAC) lung disease is reportedly a rare and serious disorder that can significantly increase morbidity and mortality. Patients with MAC lung disease can experience a range of symptoms that often worsen over time, including chronic cough, dyspnea, fatigue, fever, weight loss, chest pain and can be fatal.